DrugPatentWatch Database Preview
Details for Patent: 7,358,366
» See Plans and Pricing
Which drugs does patent 7,358,366 protect, and when does it expire?
Patent 7,358,366 protects AVANDARYL and AVANDIA and is included in two NDAs.
Protection for AVANDARYL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-five patent family members in thirty-six countries.
This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,358,366
| Title: | Thiazolidinedione derivative and its use as antidiabetic |
| Abstract: | A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione- , maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm.sup.-1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm.sup.-1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine. |
| Inventor(s): | Blackler; Paul David James (Cadiz, ES), Giles; Robert Gordon (Tonbridge, GB), Moore; Stephen (Tonbridge, GB), Sasse; Michael John (Tonbridge, GB) |
| Assignee: | SmithKline Beecham p.l.c. (Brentford, Middlesex, GB) |
| Application Number: | 11/458,471 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 7,358,366
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sb Pharmco | AVANDARYL | glimepiride; rosiglitazone maleate | TABLET;ORAL | 021700-001 | Nov 23, 2005 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Sb Pharmco | AVANDARYL | glimepiride; rosiglitazone maleate | TABLET;ORAL | 021700-002 | Nov 23, 2005 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Sb Pharmco | AVANDARYL | glimepiride; rosiglitazone maleate | TABLET;ORAL | 021700-004 | Mar 30, 2007 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,358,366
International Family Members for US Patent 7,358,366
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1607 | Start Trial | |||
| Argentina | 023560 | Start Trial | |||
| Argentina | 023750 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
